Gyeonggi-do, South Korea

Min Whan Chang

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 22.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2024

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Min Whan Chang: Innovator in Pharmaceutical Advancements

Introduction

Min Whan Chang is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target metabolic diseases. With a total of three patents to his name, Chang's work is paving the way for innovative therapeutic solutions.

Latest Patents

Chang's latest patents include a GLP-1 receptor agonist and an acid secretion inhibitor. The GLP-1 receptor agonist patent discloses novel compounds that exhibit excellent activity as GLP-1 receptor agonists. These compounds demonstrate remarkable glucose tolerance, indicating their potential as therapeutic agents for metabolic diseases. Additionally, they show excellent pharmacological safety for cardiovascular systems. The acid secretion inhibitor patent presents a novel compound that effectively inhibits acid secretion, showcasing its potential in treating related conditions.

Career Highlights

Min Whan Chang is currently associated with Il Dong Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments that address critical health issues.

Collaborations

Chang collaborates with esteemed colleagues such as Hong Chul Yoon and Kyung Mi An, contributing to a dynamic research environment that fosters innovation.

Conclusion

Min Whan Chang's contributions to pharmaceutical inventions highlight his role as a key innovator in the industry. His patents reflect a dedication to improving health outcomes through advanced therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…